Israeli scientists claim they have found a cure for cancer and there are no bad side effects and the cost is much cheaper than treatments that have proven to be somewhat successful.
Dan Aridor, chairman of the board of AEBi and CEO Dr. Ilan Morad, say their treatment, which they call MuTaTo (multi-target toxin) is essentially on the scale of a cancer antibiotic. Originally, their research started where everyone else was working on, but then they decided they wanted to do something even bigger.
They then set to work to find out what prevents other cancer treatments from working. They figured if they could discover the answer to that question, they could find a better solution and now they claim they have. When other treatments attack the cancer, one of several things happen. Those treatments attack particular cancer and cancer cells.
But cancer can mutate and become resistant to the treatment. But, it takes a while for the mutation to take place. Their plan was to use four different types of treatments which destroys the entire cell and does so before the cancer cells can mutate.
In 2018, a team of scientists won the Nobel Prize for their work on phage display in the directed evolution of new proteins – in particular, for the production of antibody therapeutics.
AEBi is doing something similar but with peptides, compounds of two or more amino acids linked in a chain. According to Morad, peptides have several advantages over antibodies, including that they are smaller, cheaper, and easier to produce and regulate.
For starters, most anti-cancer drugs attack a specific target on or in the cancer cell, he explained. Inhibiting the target usually affects a physiological pathway that promotes cancer. Mutations in the targets – or downstream in their physiological pathways – could make the targets not relevant to the cancer nature of the cell, and hence the drug attacking it is rendered ineffective.
In contrast, MuTaTo is using a combination of several cancer-targeting peptides for each cancer cell at the same time, combined with a strong peptide toxin that would kill cancer cells specifically. By using at least three targeting peptides on the same structure with a strong toxin, Morad said, “we made sure that the treatment will not be affected by mutations; cancer cells can mutate in such a way that targeted receptors are dropped by the cancer.”
“The probability of having multiple mutations that would modify all targeted receptors simultaneously decreases dramatically with the number of targets used,” Morad continued. “Instead of attacking receptors one at a time, we attack receptors three at a time – not even cancer can mutate three receptors at the same time.”
Cancer is the second most deadly disease on the planet next to heart disease, afflicting 18.1 million new people every year. If they have indeed found the cure, it will change the course of history.
They say that they will be ready to start using the new treatment in one year’s time. Let’s hope they can.